Chongqing Pharscin Wins China Clinical Trial Approval for ORIC‑1327 in Glaucoma and Ocular Hypertension
Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE: 002907) announced that its drug candidate ORIC‑1327 has received...
Pharscin Pharmaceutical
Pharscin Pharma’s PARP7 Inhibitor HSN002066C1 Wins NMPA IND Approval – First Class 1.1 Innovative Drug Enters Clinic
Chongqing Pharscin Pharmaceutical Co., Ltd. (SHE: 002907) announced that China’s National Medical Products Administration (NMPA) has...
Chongqing Pharscin’s Gabexate Mesylate Passes GQCE as First Generic in China
China-based Chongqing Pharscin Pharmaceutical Co., Ltd (SHE: 002907) announced that its gabexate mesylate has passed...